Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 145.47B, Pfizer(PFE) trades at $25.55. The stock has a price-to-earnings ratio of 14.66 and currently yields dividends of 6.8%.
On 2026-01-14, Pfizer(PFE) stock moved within a range of $25.13 to $25.71. With shares now at $25.55, the stock is trading +1.7% above its intraday low and -0.6% below the session's peak.
Trading volume for Pfizer(PFE) stock has reached 53.72M, versus its average volume of 42.43M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025. Revolution Medici...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Pfizer Tests New Migraine Drug Formulation in Early-Stage...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...
Analyst ratings
57%
of 28 ratingsMore PFE News
Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financi...
Earlier this week, Pfizer used the ASCO Gastrointestinal Cancers Symposium to share positive BREAKWATER trial data for its BRAFTOVI® combination in BRAF V600E m...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer and keeping the price target at $30.00. Claim 70% Off TipRanks Premium Unlock hedge fu...
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipel...
13:31 EST Pfizer (PFE) CEO says ‘not in our plans’ to do buybacks Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time...
13:06 EST Pfizer (PFE) CEO sees launching 10 Phase 3 GLP-1 trials this year Published first on TheFly – the ultimate source for real-time, market-moving breaki...